Evaluate
- Company typePrivate
- Founded1996
- HeadquartersLondon, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
Evaluate firmographics
Firmographics- Name
- Evaluate
- Legal name
- Evaluate, a Norstella Company
- Website
- https://evaluate.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Evaluate industry classification
Industry- Product category
- Pharmaceutical Commercial Intelligence
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Evaluate is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Evaluate business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Subscription data products: Recurring subscriptions to SaaS/data platforms including Evaluate Pharma, Evaluate Omnium, Evaluate Epi, Biomedtracker, Datamonitor Healthcare, BioSciDB, Meddevicetracker, FC+, FC365, Evaluate Medtech, Japan & Europe Drug Forecasts, Norstella Atlas CI, CDMO Intelligence, and Real World Data feeds. Built around licensed datasets delivered via web app login.
- Consulting & analytics services: Tailored advisory engagements (over 70 consultants globally) across portfolio strategy, BD&L, competitive intelligence and market sizing/forecasting. Includes Custom Model Build, Forecasting Support, and the Forecasting Audit service.
- Disease Reports (one-time report sales): One-time purchase of in-depth disease reports from the Report Store (e.g., Chronic Urticaria Disease Report priced at $16,275) covering oncology, immunology, CNS, gastroenterology, and cardiovascular/metabolic indications.
- Training and enablement services: Pharma forecasting training delivered as tailored in-person workshops, online self-paced courses, and multi-client workshops; complementary to product subscriptions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise SaaS data subscriptions (quote-based) |
| One time/ perpetual license | Pay-as-you-go | Disease Reports (one-time purchase) |
| One time/ perpetual license | Multi-year contract | FC+ forecasting software (per add-in) |
| Other | Multi-year contract | Consulting & analytics (project-based) |
| Other | Pay-as-you-go | Training programs (workshops, online courses) |
Go-to-market motion4 records
Evaluate product offering
Product offeringCore offering
Evaluate delivers AI-augmented commercial intelligence and advisory services to pharmaceutical, biotech, and life science investors. Its core offering is a portfolio of subscription data platforms (Evaluate Pharma consensus forecasts, Evaluate Omnium ML-driven pipeline forecasting, Evaluate Epi epidemiology, Biomedtracker, Datamonitor Healthcare, BioSciDB, Norstella Atlas CI) combined with a 70+ consultant professional services practice covering portfolio strategy, BD&L, competitive intelligence, and bespoke pharma forecasting model builds.
Product overview
Evaluate (a Norstella company) delivers a platform-plus-modules architecture of commercial intelligence products for the pharmaceutical industry, organised around four solution areas: Forecasting, Business Development & Licensing, Portfolio Strategy, and Competitive Intelligence. The flagship core product is Evaluate Pharma, the consensus-forecasting platform that anchors the portfolio and feeds downstream tools. Layered on top are Evaluate Omnium (ML-driven pipeline forecasting using PTRS and NPV models), Evaluate Epi (epidemiology intelligence covering 530+ diseases and 14,500+ sub-populations), regional consensus forecasts for Japan and Europe, and the Ask Ella AI analyst embedded in Evaluate Pharma and Biomedtracker. Pipeline and deal intelligence is provided through Biomedtracker, Datamonitor Healthcare, BioSciDB, and the Norstella Atlas CI agentic-AI platform. Forecasting enablement is delivered via the FC365 cloud-based platform and the FC+ Excel-based suite (with Sales+, Epi+, Onco+, and Flow+ add-ins), supplemented by the J+D Forecasting custom model build, training, and Pharma Forecasting Support services inherited from the 2024 J+D acquisition. Specialised data products include Meddevicetracker, Evaluate Medtech, CDMO Intelligence, Real World Data, and Data Feeds. A global consulting and analytics practice (70+ consultants) wraps around the data products to deliver Custom Analytics, Competitive Intelligence, and bespoke Portfolio Strategy, BD&L, and Forecasting engagements.
Differentiator
Problem solved
Functional benefit
Brands
- Evaluate Pharma: Premier consensus-forecasting platform for the biopharma industry, covering nearly 6,000 drugs with 1.5m+ historical forecasts.
- Evaluate Omnium
- Evaluate Epi
- Biomedtracker
- Datamonitor Healthcare
- Norstella Atlas CI
- BioSciDB
- Ask Ella
- J+D Forecasting
- Japan Drug Forecasts
- Europe Drug Forecasts
Products and services
- Evaluate Pharma Premier consensus-forecasting platform for the biopharma industry, covering almost 6,000 drugs with 1.5m+ historical forecasts of 10,000 products dating back to 2003. Connects consensus forecasts with pipelines across indications, therapeutic areas, and mechanisms of action to support BD&L, competitive intelligence, and commercial strategy for pharmaceutical and biotech customers.
- Evaluate Omnium Machine-learning platform that analyses millions of data points across the full clinical pipeline, including early-phase and privately-held assets, to deliver risk-adjusted peak sales, NPV modelling, PTRS scores, and ROI benchmarks for pipeline prioritisation and capital allocation.
- Evaluate Epi Evidence-based epidemiology intelligence covering 15 therapeutic areas, 530+ indications and 14,500+ sub-populations across 55 countries, providing patient segmentation, prevalence, and incidence data to underpin asset valuations and forecasts for pharma and biotech customers.
- Japan Drug Forecasts Consensus forecasts, historical sales, and sales-by-indication for the Japanese pharmaceutical market, covering nearly 2,000 marketed and R&D products and over 80% of Japan's total market value.
- Europe Drug Forecasts Country- and product-level consensus forecasts out to 2030, plus R&D pipeline and ex-factory pricing across Germany, France, Italy, England, Poland, Spain, and other key EU markets.
- Ask Ella Generative-AI analyst embedded inside Evaluate Pharma and Biomedtracker that answers plain-English questions with sourced, citable responses drawn exclusively from the licensed Evaluate datasets the subscriber already trusts. Understands indications, modalities, deal structures, and forecast models and maintains conversation context across multi-turn Q&A.
- Norstella Atlas CI Agentic AI platform purpose-built for pharma competitive intelligence, running on Norstella's curated data lake. Reasons across master drugs, trials, events, and organisations datasets (and a customer's own data via BYOD) to deliver ready-to-share competitive landscapes, drug profiles, catalyst timelines, and leadership briefings exportable to editable PowerPoint, cutting approximately 80% of manual CI assembly time.
- Biomedtracker Real-time tracking of the drug development landscape covering over 35,000 drugs and 1,800+ targets, with proprietary Likelihood-Of-Approval (LOA) and predictive POA metrics, deal summaries, patent coverage, conference coverage, and analyst commentary for pharma and biotech customers.
- Datamonitor Healthcare In-depth market analysis across 130+ disease areas with KOL insights, patient and sales forecasts, SWOT analyses on the top 45 companies, regional breakdowns, and a proprietary Drug Assessment Model for marketed and pipeline therapies.
- BioSciDB Reference database of biopharma alliances containing three decades of publicly filed deals and over 11,100 unredacted contracts obtained via FOIA disclosures, with structured Alliance Keyword search and contract-level inspection tools to support BD&L deal benchmarking.
- Meddevicetracker Provides a 360-degree view of medical device markets, companies, and products, including upcoming filing alerts, clinical trial dates, trial data, and market size information for medical device and medtech customers.
- Evaluate Medtech Enables medtech users to gauge market perceptions of their own company and portfolio, as well as competitors, clients, and potential new partners in the medtech space.
- CDMO Intelligence Intelligence solution launched on October 3, 2023 to support the rapidly expanding pharmaceutical Contract Development & Manufacturing Organization (CDMO) market and inform CDMO partnership decisions.
- Real World Data Real-world data product referenced in Evaluate's product portfolio to support evidence-based pharmaceutical decision-making.
- Data Feeds Data feed product for delivering Evaluate's commercial intelligence into client systems, enabling integration of Evaluate datasets into customer workflows.
- FC365 Collaborative, cloud-based pharma forecasting platform built on the Microsoft 365 technology stack. Retains Excel as the native forecasting tool, integrates MS Teams collaboration and Power BI visualisations, and supports multi-scenario forecasting for global pharma teams.
- FC+ Pharma Forecasting Software Excel-based pharmaceutical forecasting suite comprising specialised add-ins (Sales+ for statistical revenue/unit/patient forecasting, Epi+ for epidemiology forecasts, Onco+ for oncology patient-flow forecasting, and Flow+ for patient flow in progressive diseases), with built-in Monte Carlo, SIMSCORE, P&L, and consolidation modules.
- J+D Forecasting Solutions Suite of pharmaceutical-industry forecasting solutions acquired by Evaluate in January 2024, integrating FC+, FC365, custom models, advanced analytics, training, and GenAI technology into the Evaluate portfolio.
- Competitive Intelligence (CI) Solution Tech-enabled competitive intelligence platform powered by Norstella data, featuring modules for Pipeline, Trial Timeline, Deals, Risk & Return, Conferences, Approval Timeline, Market Size, Events & Catalysts, and News Headlines, with presentation-ready auto-generated deliverables.
- Custom Model Build Bespoke Excel-based forecast model construction delivered by J+D's forecasting specialists, claimed to reduce development time by up to 80% and cost by up to 60% versus traditional custom builds, tailored to product lifecycle stage, disease area, and organisational processes.
- Pharma Forecasting Training Pharma forecasting training delivered by J+D's forecasting specialists, available as online self-paced courses, multi-client workshops, and tailored in-person workshops covering sales, oncology, and epi-based techniques.
- Pharma Forecasting Support On-demand consultancy and support from J+D's forecasting specialists for peak-period capacity, special projects, and Forecasting Audits, delivered by teams located in the US, Europe, and the UK.
- Custom Analytics (Consulting) Pharmaceutical consulting and analytics team of 70+ consultants delivering bespoke engagements across Business Development & Licensing, Asset & Portfolio Strategy, and Competitive Intelligence, leveraging Evaluate's data and Norstella's broader expertise.
Companies that use Evaluate
Customer profileIdeal customer profiles1 record
Evaluate technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability9 records
Feature8 records
Evaluate partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights6 records
Evaluate competitors and assessment
Company assessmentBroad incumbents
- IQVIA: IQVIA is the largest life sciences commercial intelligence and clinical research provider globally, offering R&D solutions, real-world evidence, and technology. It competes with Evaluate across pharma commercial intelligence, market sizing, and forecasting, but operates at much greater scale across a broader portfolio.
- Veeva Systems: Veeva provides life sciences cloud software (CRM, Vault, Veeva Compass data) used across commercial, medical and R&D workflows. It competes indirectly with Evaluate by embedding commercial data, patient data and AI into pharma operating platforms rather than selling standalone intelligence subscriptions.
- S&P Global Market Intelligence: S&P Global Market Intelligence provides cross-sector financial and corporate data with healthcare-adjacent datasets. It is comparable as a broader commercial intelligence incumbent but lacks Evaluate's depth of pharma-specific drug, trial and forecast coverage.
Direct peers
- Clarivate: Clarivate provides pharmaceutical and biopharma intelligence (Cortellis, Drug Safety, BioWorld) and competes directly with Evaluate on drug pipeline, patent, deal and forecasting data used by life sciences enterprises. Both serve the same pharma BD&L, portfolio strategy and CI workflows with overlapping product categories.
- Citeline (Norstella): Citeline is a sister company of Evaluate under Norstella and provides clinical trial intelligence (TrialTrove, Sitetrove, PharmaProject) with deep coverage of trial design, sites, and outcomes. Both brands target the same pharma customer for pipeline and competitive intelligence but with complementary rather than overlapping datasets.
- Informa Pharma Intelligence: Informa Pharma Intelligence offers Citeline-derived trial and pipeline data plus Scrip, Meddevicetracker competitor insights and Pink Sheet regulatory intelligence. It competes directly with Evaluate's Biomedtracker and Evaluate Pharma in serving pharma strategy, BD&L and CI teams.
- GlobalData: GlobalData provides pharma market sizing, drug forecasts, epidemiology and company intelligence through its Pharma and Healthcare units. It overlaps directly with Evaluate Pharma, Evaluate Epi and Datamonitor Healthcare on consensus forecasts and disease-level market analysis.
Emerging players
- Definitive Healthcare: Definitive Healthcare provides U.S.-centric healthcare commercial intelligence covering providers, payers and life sciences accounts. It is comparable as a pharma commercial intelligence platform but skews more toward U.S. healthcare provider and account data than Evaluate's global drug-and-pipeline focus.
- AlphaSense: AlphaSense is an AI-driven market intelligence and enterprise search platform used by life sciences strategy and CI teams. It is comparable to Ask Ella and Norstella Atlas CI as an AI-augmented research layer but sources primarily from broker research and public documents rather than Evaluate's licensed pharma datasets.
- CBPartners: CBPartners is a boutique pharma pricing, market access and value strategy consultancy that directly competes with Evaluate's Consulting & Analytics practice for BD&L, pricing, and forecasting engagements with global pharma clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Evaluate social profiles
Digital presenceEvaluate financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evaluate leadership team
Management profileNumber of profiles
Profiles9 records
Evaluate subsidiaries and ownership
Company hierarchySubsidiaries14 records
Evaluate funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evaluate M&A and investment
M&A and investmentM&A3 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evaluate
What does Evaluate do?
Evaluate delivers AI-augmented commercial intelligence and advisory services to pharmaceutical, biotech, and life science investors. Its core offering is a portfolio of subscription data platforms (Evaluate Pharma consensus forecasts, Evaluate Omnium ML-driven pipeline forecasting, Evaluate Epi epidemiology, Biomedtracker, Datamonitor Healthcare, BioSciDB, Norstella Atlas CI) combined with a 70+ consultant professional services practice covering portfolio strategy, BD&L, competitive intelligence, and bespoke pharma forecasting model builds.
Is Evaluate a public or private company?
Evaluate is a private company. It is classified as corporate owned and is currently operating.
When was Evaluate founded?
Evaluate was founded in 1996. It employs 101 to 250 people.
Where is Evaluate based?
Evaluate is headquartered in London, United Kingdom, in the Europe region.
How does Evaluate make money?
Four revenue lines are on record. Subscription data products are the primary driver. The others are consulting & analytics services, disease Reports (one-time report sales) and training and enablement services.
Who are Evaluate's main competitors?
Broad incumbents on record are IQVIA, Veeva Systems and S&P Global Market Intelligence. Direct peers are Clarivate, Citeline (Norstella), Informa Pharma Intelligence and GlobalData. Emerging players are Definitive Healthcare, AlphaSense and CBPartners.
Does Evaluate have an API?
No public API is recorded for Evaluate.
What industry is Evaluate in?
Evaluate's product category is Pharmaceutical Commercial Intelligence. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 54169 and its SIC code is 7372.